How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.
Researchers at MIT's CSAIL published a design for Recursive Language Models (RLM), a technique for improving LLM performance on long-context tasks. RLMs use a programming environment to recursively ...
Hosted on MSN
JPMorgan boosts rating on Recursion Pharmaceuticals (RXRX) amid AI-driven drug pipeline
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ranks among the best AI stocks to buy according to analysts. On December 17, JPMorgan raised Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from a Neutral ...
Hosted on MSN
Recursion Pharmaceuticals projects $100M synergies in 2025 amid advancing pipeline and partnerships
CEO Chris Gibson highlighted significant progress in 2024, including clinical data readouts from REC-617 and REC-994, which showed early efficacy signals and robust safety, respectively. REC-617, a ...
Replication-dependent histone mRNAs, which encode the most abundant histone proteins, are the only known cellular mRNAs that are not polyadenylated. Instead they end in a conserved stem–loop that ...
Business.com aims to help business owners make informed decisions to support and grow their companies. We research and recommend products and services suitable for various business types, investing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results